Tirzepatide denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Quantity Limits to Tirzepatide

Quantity-limit (QL) denials mean BCBS will cover tirzepatide but only up to a defined dispensing threshold per fill or per period. These limits are set by BCBS's pharmacy benefit manager and may not align with the dose your prescriber determined is clinically appropriate for your case. QL denials are appealable when the prescribed quantity is supported by the FDA-approved prescribing label and documented clinical need.

Do not assume the quantity limit reflects the maximum safe or effective dose — refer to the FDA-approved prescribing label for the authorized dosing range, and have your prescriber document why the prescribed quantity is medically necessary.

## Your Federal Appeal Rights

Quantity-limit denials are subject to the same appeal rights as other coverage denials. Under ACA §2719 and ERISA §503, you are entitled to a full internal review and, if needed, an independent external review. File your internal appeal within 180 days of the denial notice. External review is generally available for approximately 4 months after the internal process concludes. Request expedited review if the quantity restriction is causing or risking acute clinical deterioration.

## Concrete Appeal Steps

1. Get the denial in writing — confirm the specific quantity limit applied and the policy basis for it. 2. Request BCBS's quantity-limit policy for tirzepatide, including any exception criteria. 3. Review the FDA label to confirm the prescribed quantity falls within the authorized dosing framework. 4. Have your prescriber document the clinical rationale for the specific prescribed quantity (e.g., titration schedule, body weight considerations, prior dosing history). 5. File the internal appeal with the prescriber's medical-necessity letter and supporting chart documentation. 6. If denied internally, proceed to external review.

## Documentation to Gather

• Prescriber letter explaining the quantity: should reference the FDA-approved dosing range and explain why the prescribed quantity is necessary for this specific patient
• Titration records: if the quantity reflects an active titration schedule, document each prior dose, date, and clinical response
• Clinical response data: chart entries showing response (or inadequate response) at lower quantities, if applicable
• Diagnosis and severity documentation: establishes the clinical context requiring this treatment at this quantity

## Criteria-Mapping Structure

Obtain BCBS's published quantity-limit exception criteria. Map each criterion to a specific chart entry. Common exception arguments include: (1) the FDA label authorizes the prescribed quantity; (2) the patient's documented clinical response requires the prescribed quantity; (3) a lower quantity would result in under-treatment with documented clinical consequences. Your prescriber's letter should address each criterion explicitly.